Safety and efficacy of telbivudine in late pregnancy to prevent mother‐to‐child transmission of hepatitis B virus: A multicenter prospective cohort study
Authors:
- 28 November 2017
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 25 (4) , 429-437
Abstract
Summary: Infection of hepatitis B virus (HBV) occurs in ~10% of infants of HBV‐infected mothers with positive hepatitis B e antigen (HBeAg) after immunoprophylaxis. We aimed to evaluate the safety and efficacy of telbivudine used during late pregnancy for preventing mother‐to‐child transmission of HBV. We conducted a multicenter prospective cohort study in 5 hospitals from 2012 to 2014, which enrolled HBV‐infected singleton pregnant women with positive HBeAg. By their choice, women were divided into therapy (telbivudine 600 mg/day, from gestation 28‐32 weeks to 3‐4 weeks postpartum) and control (no antiviral agent) groups. Infants received passive‐active immunoprophylaxis and follow‐up at the age of 7‐14 months. Totally, 328 pregnant women were included: 149 in the telbivudine group and 179 in the control group. Baseline HBV DNA levels were similar in the 2 groups (7.43 vs 7.37 log10 IU/mL, P = .711). At delivery, HBV DNA levels in the telbivudine and control groups were 3.80 and 7.26 log10 IU/mL, respectively (P < .0001). Of the infants, 128 (85.9%) in the telbivudine group and 156 (87.2%) in the control group were followed up. No infant in the telbivudine group had chronic infection, while 2 (1.28%) infants in the control group did (P = .503). Three (2.34%) infants in the telbivudine group, but none in the control group, had severe congenital or developmental abnormalities (P = .090). The data indicate that telbivudine may block perinatal HBV transmission. However, larger studies are required to clarify whether anti‐HBV therapy in pregnancy is associated with severe adverse effects in the foetuses and infants.Keywords
Funding Information
- National Health and Family Planning Commission of the People's Republic of China (201402029)
- Jiangsu Provincial Department of Education (F22012047)
This publication has 37 references indexed in Scilit:
- Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virusJournal of Infection, 2013
- Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancyJournal of Viral Hepatitis, 2012
- Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-based study in ChinaBMC Infectious Diseases, 2012
- A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant womenVaccine, 2012
- Protective Effect of Hepatitis B Vaccine Combined with Two-Dose Hepatitis B Immunoglobulin on Infants Born to HBsAg-Positive MothersPLOS ONE, 2011
- Virologic factors associated with failure to passive–active immunoprophylaxis in infants born to HBsAg‐positive mothersJournal of Viral Hepatitis, 2011
- A novel hepatitis B virus mutant coexisting with wild type virus in a carrier with negative HBsAg yet positive HBeAg and anti-HBsJournal of Clinical Virology, 2009
- Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 22‐Year Follow‐Up Study and Response to a Booster DoseThe Journal of Infectious Diseases, 2009
- Hepatitis B post‐partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristicsJournal of Gastroenterology and Hepatology, 2006
- Molecular epidemiology of hepatitis B virus vaccine variants in SingaporeVaccine, 1995